DBV Technologies S.A. (DBV.PA)
EUR 0.61
(1.17%)
EUR 0.61
(1.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -79.53 Million EUR | 7.45% |
| 2022 | -76.67 Million USD | 3.84% |
| 2021 | -79.77 Million USD | 19.53% |
| 2020 | -132.7 Million EUR | 23.64% |
| 2019 | -159.84 Million EUR | 12.26% |
| 2018 | -172.53 Million EUR | -9.8% |
| 2017 | -150.77 Million EUR | -42.58% |
| 2016 | -120.39 Million EUR | -150.5% |
| 2015 | -49.14 Million EUR | -67.02% |
| 2014 | -27.73 Million EUR | -8.76% |
| 2013 | -22.25 Million EUR | -55.66% |
| 2012 | -16.8 Million EUR | -84.46% |
| 2011 | -9.1 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -26.42 Million USD | -175.6% |
| 2024 Q2 | -31.41 Million USD | -18.54% |
| 2023 Q1 | -19.08 Million USD | 26.59% |
| 2023 FY | - EUR | 7.45% |
| 2023 Q4 | -10.34 Million USD | 43.48% |
| 2023 Q3 | -18.3 Million USD | 17.86% |
| 2023 Q2 | -22.28 Million USD | -16.75% |
| 2022 Q3 | -16.06 Million USD | 26.88% |
| 2022 Q4 | -25.99 Million USD | -61.76% |
| 2022 Q1 | -13.84 Million USD | 9.62% |
| 2022 Q2 | -21.97 Million USD | -58.74% |
| 2022 FY | - USD | 3.84% |
| 2021 Q1 | -28.15 Million USD | 57.67% |
| 2021 Q2 | -23.99 Million USD | 14.76% |
| 2021 Q3 | -20.86 Million USD | 13.05% |
| 2021 Q4 | -15.31 Million USD | 26.59% |
| 2021 FY | - USD | 19.53% |
| 2020 Q1 | -39.67 Million USD | 15.87% |
| 2020 Q3 | -26.57 Million USD | -435.1% |
| 2020 FY | - EUR | 23.64% |
| 2020 Q4 | -66.51 Million USD | -150.34% |
| 2020 Q2 | 7.92 Million USD | 119.99% |
| 2019 FY | - EUR | 12.26% |
| 2019 Q4 | -47.15 Million EUR | -60.16% |
| 2019 Q1 | -43.12 Million USD | 19.67% |
| 2019 Q2 | -43.71 Million USD | -1.38% |
| 2019 Q3 | -29.44 Million EUR | 32.65% |
| 2018 FY | - EUR | -9.8% |
| 2018 Q4 | -53.68 Million EUR | -7.56% |
| 2018 Q3 | -49.9 Million EUR | -16.52% |
| 2018 Q2 | -42.83 Million USD | 5.21% |
| 2018 Q1 | -45.18 Million USD | -4.39% |
| 2017 Q2 | -39.97 Million USD | -7.06% |
| 2017 Q3 | -42.64 Million USD | -6.67% |
| 2017 Q4 | -43.28 Million USD | -1.51% |
| 2017 FY | - EUR | -42.58% |
| 2017 Q1 | -37.33 Million USD | -7.6% |
| 2016 Q1 | -27.76 Million USD | -68.69% |
| 2016 FY | - EUR | -150.5% |
| 2016 Q4 | -34.7 Million USD | 6.3% |
| 2016 Q3 | -37.03 Million USD | -36.81% |
| 2016 Q2 | -27.07 Million USD | 2.49% |
| 2015 Q1 | -6.41 Million USD | 13.88% |
| 2015 FY | - EUR | -67.02% |
| 2015 Q4 | -16.45 Million USD | 2.68% |
| 2015 Q3 | -16.91 Million USD | -85.03% |
| 2015 Q2 | -9.13 Million USD | -42.45% |
| 2014 Q4 | -7.45 Million USD | 3.9% |
| 2014 FY | - EUR | -8.76% |
| 2014 Q1 | -7.18 Million USD | 9.58% |
| 2014 Q2 | -9.06 Million USD | -26.19% |
| 2014 Q3 | -7.75 Million USD | 14.47% |
| 2013 Q2 | -5.24 Million USD | -1.46% |
| 2013 Q3 | -7.8 Million USD | -48.78% |
| 2013 Q4 | -7.94 Million USD | -1.75% |
| 2013 FY | - EUR | -55.66% |
| 2013 Q1 | -5.17 Million USD | -3.17% |
| 2012 Q3 | -4.88 Million USD | 0.0% |
| 2012 FY | - EUR | -84.46% |
| 2012 Q4 | -5.01 Million USD | -2.66% |
| 2011 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -2317.35% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 40.295% |
| Adocia SA | -22.73 Million EUR | -249.863% |
| Aelis Farma SA | -6.34 Million EUR | -1153.046% |
| Biophytis S.A. | -13.8 Million EUR | -476.143% |
| Advicenne S.A. | -6.24 Million EUR | -1173.716% |
| genOway Société anonyme | 6.35 Million EUR | 1352.306% |
| IntegraGen SA | -52.5 Thousand EUR | -151378.609% |
| Medesis Pharma S.A. | -3.84 Million EUR | -1968.484% |
| Neovacs S.A. | -8.44 Million EUR | -841.244% |
| NFL Biosciences SA | -4.04 Million EUR | -1864.062% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 109752.301% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -2667.752% |
| Sensorion SA | -22.31 Million EUR | -256.42% |
| Theranexus Société Anonyme | -7.38 Million EUR | -976.598% |
| TME Pharma N.V. | -5.07 Million EUR | -1468.037% |
| Valbiotis SA | -6.95 Million EUR | -1043.506% |
| TheraVet SA | -517.33 Thousand EUR | -15273.145% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -320.442% |
| argenx SE | -199.5 Million EUR | 60.136% |
| BioSenic S.A. | -6.79 Million EUR | -1070.259% |
| Celyad Oncology SA | -7.76 Million EUR | -924.486% |
| Galapagos NV | 51.03 Million EUR | 255.83% |
| Genfit S.A. | -28.05 Million EUR | -183.522% |
| GeNeuro SA | -14.31 Million EUR | -455.472% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -430.913% |
| Innate Pharma S.A. | -7.57 Million EUR | -949.496% |
| Inventiva S.A. | -101.84 Million EUR | 21.912% |
| MaaT Pharma SA | -19.74 Million EUR | -302.892% |
| MedinCell S.A. | -20.04 Million EUR | -296.742% |
| Nanobiotix S.A. | -34.01 Million EUR | -133.784% |
| Onward Medical N.V. | -35.23 Million EUR | -125.722% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -1693.918% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | -241.833% |
| Oxurion NV | -16.72 Million EUR | -375.407% |
| Pharming Group N.V. | 4.98 Million EUR | 1696.695% |
| Poxel S.A. | -12.17 Million EUR | -553.016% |
| GenSight Biologics S.A. | -21.73 Million EUR | -265.995% |
| Transgene SA | -27.02 Million EUR | -194.297% |
| Financière de Tubize SA | 184.57 Thousand EUR | 43189.55% |
| UCB SA | 1.26 Billion EUR | 106.267% |
| Valneva SE | -64.51 Million EUR | -23.271% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | -180.502% |